Cargando…
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted monotherapies have been largely disappointing, and any potential success has been limited by the lack of validated predictive biomarkers for...
Autores principales: | Simpson, Aaron, Petnga, Wilfride, Macaulay, Valentine M., Weyer-Czernilofsky, Ulrike, Bogenrieder, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610669/ https://www.ncbi.nlm.nih.gov/pubmed/28815409 http://dx.doi.org/10.1007/s11523-017-0514-5 |
Ejemplares similares
-
CHK1 inhibition exacerbates replication stress induced by IGF blockade
por: Wu, Xiaoning, et al.
Publicado: (2021) -
Therapeutic Targeting of the IGF Axis
por: Osher, Eliot, et al.
Publicado: (2019) -
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide
por: Ramcharan, Roger, et al.
Publicado: (2015) -
Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus
por: Kim, Min Sun, et al.
Publicado: (2015) -
Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer
por: Ireland, Lucy, et al.
Publicado: (2018)